56,081 results match your criteria Clear Cell Renal Cell Carcinoma


Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes from the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort.

Urology 2021 Jun 12. Epub 2021 Jun 12.

Urology Division, Department of Surgery, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. Electronic address:

Objective: To characterize proportion of patients receiving adrenalectomy, adrenal involvement prevalence and oncologic outcomes of routine adrenalectomy in contemporary practice. Ipsilateral adrenalectomy was once standard during radical nephrectomy. However, benefit of routine adrenalectomy has been questioned because adrenal involvement of renal cell carcinoma (RCC) is low. Read More

View Article and Full-Text PDF

EZR-ROS1 fusion renal cell carcinoma mimicking urothelial carcinoma: report of a previously undescribed gene fusion in renal cell carcinoma.

Virchows Arch 2021 Jun 14. Epub 2021 Jun 14.

Department of Pathology, The University of Chicago Medicine, 5841 S. Maryland Avenue, Chicago, IL, 60637, USA.

A subset of renal cell carcinomas harbor gene fusions, and we report the first case of an EZR-ROS1 fusion in renal cell carcinoma. A 47-year-old female presented with hematuria and a mass involving the renal pelvis. Renal biopsy revealed a tumor with solid and tubular architecture that was diffusely positive for PAX8, CK7, and vimentin; retained expression of INI1; focally positive for P504S; and negative for GATA3 and TFE3. Read More

View Article and Full-Text PDF

An update on the pathology of collecting duct & papillary renal cell carcinoma with a discussion of SNP-Arrays as an emerging laboratory technique.

Authors:
Sounak Gupta

Urol Oncol 2021 Jun 11. Epub 2021 Jun 11.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. Electronic address:

The diagnostic criteria and management of renal cell carcinoma (RCC) has evolved significantly in the last two decades. Increased molecular profiling of RCC has yielded further refinement of existing diagnostic categories. This is particularly true for papillary RCC, which has evolved into multiple molecularly distinct entities. Read More

View Article and Full-Text PDF

Urothelial carcinoma of the graft kidney with molecular analyses: a rare case report.

Diagn Pathol 2021 Jun 14;16(1):53. Epub 2021 Jun 14.

Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Background: Malignancy after transplantation is a leading cause of death among kidney transplant recipients. However, donor-derived malignancies are rare. We report a case of a high grade papillary urothelial carcinoma arising in a transplanted kidney. Read More

View Article and Full-Text PDF

[Complete Remission of Metastatic Renal Cell Carcinoma with Invasion of the Duodenum and Pancreas after Treatment with Nivolumab Plus Ipilimumab Followed by Axitinib and Surgery : A Case Report].

Hinyokika Kiyo 2021 May;67(5):197-203

The Department of Urology, Kyoto University Hospital.

A man in his 60s was diagnosed with clear cell carcinoma of the right kidney with multiple lung metastases, tumor thrombus of the inferior vena cava (IVC), and invasion of the duodenum and pancreas. Ipilimumab plus nivolumab was administered as first-line therapy. After 3 treatment courses, computed tomography (CT) demonstrated a slight decrease in the size of the primary tumor and lung metastases. Read More

View Article and Full-Text PDF

Significant difference in response of malignant tumor cells of individual patients to photodynamic treatment as revealed by digital holographic microscopy.

J Photochem Photobiol B 2021 Jun 3;221:112235. Epub 2021 Jun 3.

Ioffe Institute, Russian Academy of Sciences, St. Petersburg, Russia.

The investigation of in-vitro response of cell cultures derived from tumor material of individual patients with similar tumor localizations to photodynamic treatment is presented. Tumor types included in the research were renal cell carcinoma, melanoma and alveolar, synovial, lypo- and osteo- sarcomas. Long-term observations of treatment-induced morphological changes in cells were performed by means of digital holographic microscopy. Read More

View Article and Full-Text PDF

Analyzing and Validating the Prognostic Value of a TNF-Related Signature in Kidney Renal Clear Cell Carcinoma.

Front Mol Biosci 2021 28;8:689037. Epub 2021 May 28.

The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.

Kidney renal clear cell carcinoma (KIRC) has the highest incidence rate in renal cell carcinoma (RCC). Although bioinformatics is widely used in cancer, few reliable biomarkers of KIRC have been found. Therefore, continued efforts are required to elucidate the potential mechanism of the biogenesis and progression of KIRC. Read More

View Article and Full-Text PDF

Transcription Factors BARX1 and DLX4 Contribute to Progression of Clear Cell Renal Cell Carcinoma Promoting Proliferation and Epithelial-Mesenchymal Transition.

Front Mol Biosci 2021 26;8:626328. Epub 2021 May 26.

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Dysregulation of transcription factors contributes to the carcinogenesis and progression of cancers. However, their roles in clear cell renal cell carcinoma remain largely unknown. This study aimed to evaluate the clinical significance of TFs and investigate their potential molecular mechanisms in ccRCC. Read More

View Article and Full-Text PDF

Identification of an m6A-Related lncRNA Signature for Predicting the Prognosis in Patients With Kidney Renal Clear Cell Carcinoma.

Front Oncol 2021 26;11:663263. Epub 2021 May 26.

Department of Urology, Affiliated Zhongda Hospital of Southeast University, Nanjing, China.

Purpose: This study aimed to construct an m6A-related long non-coding RNAs (lncRNAs) signature to accurately predict the prognosis of kidney clear cell carcinoma (KIRC) patients using data obtained from The Cancer Genome Atlas (TCGA) database.

Methods: The KIRC patient data were downloaded from TCGA database and m6A-related genes were obtained from published articles. Pearson correlation analysis was implemented to identify m6A-related lncRNAs. Read More

View Article and Full-Text PDF

Comparison of Different Machine Models Based on Contrast-Enhanced Computed Tomography Radiomic Features to Differentiate High From Low Grade Clear Cell Renal Cell Carcinomas.

Front Oncol 2021 26;11:659969. Epub 2021 May 26.

CT/MRI Room, Affiliated Hospital of Hebei University, Baoding, China.

Purpose: This study was to investigate the role of different radiomics models with enhanced computed tomography (CT) scan in differentiating low from high grade renal clear cell carcinomas.

Materials And Methods: CT data of 190 cases with pathologically confirmed renal cell carcinomas were collected and divided into the training set and testing set according to different time periods, with 122 cases in the training set and 68 cases in the testing set. The region of interest (ROI) was delineated layer by layer. Read More

View Article and Full-Text PDF

Advanced Renal-Cell Carcinoma Pseudoprogression After Combined Immunotherapy: Case Report and Literature Review.

Front Oncol 2021 28;11:640447. Epub 2021 May 28.

Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.

Treatment with a combination of programmed cell death-1 (PD-1) blocker and cytokine-induced killer (CIK) cells has improved outcome in cancer patients but is also associated with various patterns of responses. Pseudoprogression is a unique and uncommon phenomenon with no clear criteria for rapid diagnosis. Although some reports of pseudoprogression during immunotherapy exist, there are few reports of pseudoprogression occurring twice in the same patient. Read More

View Article and Full-Text PDF

Uncontrolled Confounders May Lead to False or Overvalued Radiomics Signature: A Proof of Concept Using Survival Analysis in a Multicenter Cohort of Kidney Cancer.

Front Oncol 2021 27;11:638185. Epub 2021 May 27.

Department of Radiology, Columbia University Irving Medical Center, New York, NY, United States.

Purpose: We aimed to explore potential confounders of prognostic radiomics signature predicting survival outcomes in clear cell renal cell carcinoma (ccRCC) patients and demonstrate how to control for them.

Materials And Methods: Preoperative contrast enhanced abdominal CT scan of ccRCC patients along with pathological grade/stage, gene mutation status, and survival outcomes were retrieved from The Cancer Imaging Archive (TCIA)/The Cancer Genome Atlas-Kidney Renal Clear Cell Carcinoma (TCGA-KIRC) database, a publicly available dataset. A semi-automatic segmentation method was applied to segment ccRCC tumors, and 1,160 radiomics features were extracted from each segmented tumor on the CT images. Read More

View Article and Full-Text PDF

Delivery of miR-224-5p by Exosomes from Cancer-Associated Fibroblasts Potentiates Progression of Clear Cell Renal Cell Carcinoma.

Comput Math Methods Med 2021 24;2021:5517747. Epub 2021 May 24.

Department of Urology, Tangshan Central Hospital, 063000 Tangshan, China.

Objectives: Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma. Cancer-associated fibroblasts (CAFs) as the primary components of cancer stroma can affect tumor progression by secreting exosomes, while exosomes are carriers for proteins, nucleic acids, and other agents that responsible for delivery of biological information. Given this, exosomes derived from CAFs are emerging as promising biomarkers in clinical cancer diagnosis. Read More

View Article and Full-Text PDF

High-dose-rate surface brachytherapy as a treatment option for renal cell carcinoma cutaneous metastases.

J Contemp Brachytherapy 2021 Jun 7;13(3):331-337. Epub 2021 May 7.

Brachytherapy Department, Greater Poland Cancer Centre, Poznan', Poland.

Purpose: The aim of this study was to present a case of complete clinical response of renal clear cell carcinoma cutaneous metastases after high-dose-rate surface brachytherapy (HDR sBT).

Material And Methods: An 81-year-old female diagnosed with stage IV clear cell renal carcinoma reported to our center with painful relapse of two cutaneous metastases after a previous metastasectomy. The patient was disqualified from systemic therapy due to comorbidities, and qualified to attempt a treatment using HDR sBT. Read More

View Article and Full-Text PDF

METTL14 Acts as a Potential Regulator of Tumor Immune and Progression in Clear Cell Renal Cell Carcinoma.

Front Genet 2021 28;12:609174. Epub 2021 May 28.

Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Clear cell renal cell carcinoma (ccRCC) is characterized by its insensitivity to chemoradiotherapy and lacks effective diagnostic and prognostic biomarkers. In this study, we focused on the role of m6A RNA methylation regulators for tumor immunity. Based on the expression of 20 m6A regulators, consensus clustering was performed to divide patients into cluster1/cluster2 and showed that there was a survival difference between the two clusters. Read More

View Article and Full-Text PDF

A rare case of giant chromophobe renal cell carcinoma with sarcomatoid differentiation: Treatment and prognosis.

J Cancer Res Ther 2021 Apr-Jun;17(2):602-605

Department of Pathology, JIPMER, Puducherry, India.

Chromophobe renal cell carcinoma (RCC) with sarcomatoid differentiation is an infrequent entity. In the current era of advanced imaging techniques, RCCs are usually detected in early stages, and a localized giant tumor is rarely encountered. Recently, we encountered a patient with a localized giant RCC, which was 36 cm in the largest dimension and weighing 5. Read More

View Article and Full-Text PDF

A rare case of bilateral synchronous renal tumors with different histology successfully treated with bilateral partial nephrectomy.

J Cancer Res Ther 2021 Apr-Jun;17(2):593-595

Department of Biomedical Engineering, MIET, Bhubaneswar, Odisha, India.

Renal cell carcinoma (RCC) accounts for about 85% of all renal neoplasms, 60% of which are diagnosed incidentally. Most are unilateral, but bilateral tumors, synchronous or asynchronous, have been found in 2%-4% of reported sporadic cases. The occurrence of synchronous bilateral renal neoplasms with different histology in the same individual is very rare. Read More

View Article and Full-Text PDF

Recurrence of renal cell carcinoma after three decades in an octogenarian: Small molecules adding life to years.

J Cancer Res Ther 2021 Apr-Jun;17(2):584-586

Department of Medical Oncology and Hematology, Amrita Institute of Medical Sciences, Ponekkara, Kochi, Kerala, India.

Renal cell carcinoma (RCC) is the most common primary renal neoplasm. About a half of our patients relapse after primary treatment. We present here a case of RCC with solitary metastasis to the pleura which occurred 32 years after nephrectomy. Read More

View Article and Full-Text PDF

Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma.

J Cancer Res Ther 2021 Apr-Jun;17(2):420-425

Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.

Objectives: To investigate the relationship between gender, body mass index (BMI), and prognosis in renal cell carcinoma (RCC) patients.

Materials And Methods: We retrospectively reviewed 1353 patients with RCC who underwent a partial or radical nephrectomy between 1988 and 2015. The association among sex, BMI, stage, grade, overall survival (OS), and recurrence-free survival (RFS) was analyzed. Read More

View Article and Full-Text PDF

Active surveillance in renal tumors: Clinical and oncological outcomes.

J Cancer Res Ther 2021 Apr-Jun;17(2):414-419

Department of Urology, La Paz University Hospital; Universidad Autonoma de Madrid; La Paz University Hospital Institute for Health Research (IdiPAZ), Madrid, Spain.

Context: Some patients diagnosed with small renal solid masses or complex cystic lesions may benefit from active surveillance (AS) instead of immediate treatment.

Aims: Report our series of patients undergoing AS for small renal solid and complex cystic lesions, and compare growth rates and outcomes between both types of lesions.

Materials And Methods: A retrospective review AS database for renal lesions was conducted. Read More

View Article and Full-Text PDF

Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib.

J Cancer Res Ther 2021 Apr-Jun;17(2):408-413

Department of Internal Medicine, Division of Medical Oncology, Gazi University Faculty of Medicine, Ankara, Turkey.

Objective: Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study evaluates ezrin expression in sunitinib-treated metastatic clear cell renal cell carcinoma (ccRCC) patients and elucidates its role as a possible marker for survival.

Materials And Methods: The expression of ezrin was measured by immunohistochemistry in 80 patients with ccRCC treated by first-line sunitinib between January 2007 and June 2012. Read More

View Article and Full-Text PDF

MDCT evaluation of synchronous breast carcinoma and other solid malignancies.

Authors:
Adel El-Badrawy

Breast Dis 2021 Jun 2. Epub 2021 Jun 2.

Radiology Department, Mansoura University Faculty of Medicine, Mansoura, Dakahlya, Egypt.

Background: Multiple primary malignancies are two or more malignancies in an individual without any relationship between the tumors. The development of improved diagnostic techniques, increased survival of cancer patients and the growing life expectancy have all contributed to the increased frequency of this phenomenon.

Objective: The aim of this study is to review the multidetector computed tomography (MDCT) findings of synchronous breast carcinoma and other solid malignancies. Read More

View Article and Full-Text PDF

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports.

Eur J Nucl Med Mol Imaging 2021 Jun 12. Epub 2021 Jun 12.

Department of Medical Imaging, Nuclear Medicine, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.

In the past decade, a growing body of literature has reported promising results for prostate-specific membrane antigen (PSMA)-targeted radionuclide imaging and therapy in prostate cancer. First clinical studies evaluating the efficacy of [Lu]Lu-PSMA radioligand therapy (PSMA-RLT) demonstrated favorable results in prostate cancer patients. [Lu]Lu-PSMA is generally well tolerated due to its limited side effects. Read More

View Article and Full-Text PDF

Physiological and pathological functions of βB2-crystallins in multiple organs: a systematic review.

Aging (Albany NY) 2021 Jun 11;13. Epub 2021 Jun 11.

Department of Obstetrics and Gynecology, Changhai Hospital, Naval Military Medical University, Yangpu, Shanghai 200433, China.

Crystallins, the major constituent proteins of mammalian lenses, are significant not only for the maintenance of eye lens stability, transparency, and refraction, but also fulfill various physiopathological functions in extraocular tissues. βB2-crystallin, for example, is a multifunctional protein expressed in the human retina, brain, testis, ovary, and multiple tumors. Mutations in the βB2 crystallin gene or denaturation of βB2-crystallin protein are associated with cataracts, ocular pathologies, and psychiatric disorders. Read More

View Article and Full-Text PDF

Capmatinib-Induced Pseudo-Acute Kidney Injury: A Case Report.

Am J Kidney Dis 2021 Jun 9. Epub 2021 Jun 9.

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota. Electronic address:

We present a case of pseudo acute kidney injury (AKI) following capmatinib therapy in an 84-year-old male with combined non-small cell (adenocarcinoma) and small cell lung cancer with MET Exon 14 skipping mutation. His past medical history was significant for chronic kidney disease (CKD) stage 3 with a baseline serum creatinine (SCr) of 1.6 mg/dl rising to 2. Read More

View Article and Full-Text PDF

Cabozantinib promotes erythroid differentiation in K562 erythroleukemia cells through global changes in gene expression and JNK activation.

Cancer Gene Ther 2021 Jun 11. Epub 2021 Jun 11.

Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University, Taipei, Taiwan.

Cabozantinib is a potent tyrosine kinase inhibitor with multiple targets including MET, VEGFR2, RET, KIT, and FLT3. Cabozantinib is widely used for the treatment of medullary thyroid cancer and renal cell carcinoma. We recently suggested cabozantinib as a potential therapeutic alternative for acute myeloid leukemia (AML) patients with FLT3-internal tandem duplication (FLT3-ITD). Read More

View Article and Full-Text PDF

Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists' ever-expanding differential diagnosis for a heterogeneous group of entities.

Urol Oncol 2021 Jun 8. Epub 2021 Jun 8.

Department of Pathology, University of Michigan Medical School, Ann Arbor, MI. Electronic address:

Although papillary renal cell carcinoma has historically been classified as either type 1 or type 2, data from The Cancer Genome Atlas (TCGA) has demonstrated significant genomic heterogeneity in tumors classified as "type 2 papillary renal cell carcinoma" (T2PRCC). Papillary renal cell carcinoma is expected to have a favorable clinical course compared to clear cell renal cell carcinoma (CCRCC). However, tumors with poor outcome more similar to CCRCC were included in the T2PRCC cohort studied by the TCGA. Read More

View Article and Full-Text PDF

"Collecting duct carcinoma of the kidney: diagnosis and implications for management".

Urol Oncol 2021 Jun 8. Epub 2021 Jun 8.

Department of Pathology, City of Hope National Medical Center, Duarte, CA. Electronic address:

Collecting duct carcinoma of the kidney is a rare and aggressive subtype of renal cell carcinoma (RCC) arising from the distal convoluted tubules. At the time of diagnosis, patients are more frequently symptomatic, with advanced locoregional stage, and have metastatic disease. The 2016 WHO Classification of Tumours of the Urinary System defined diagnostic criteria for this entity. Read More

View Article and Full-Text PDF

Race/ethnicity and advanced stage of renal cell carcinoma in adults: results from surveillance, epidemiology, and end results program 2007-2015.

Eur J Cancer Prev 2021 Jun 10. Epub 2021 Jun 10.

Division of Medical and Population Health Sciences Research Department of Translational Medicine, Herbert Wertheim College of Medicine at Florida International University, Miami, Florida, USA.

Non-Hispanic Blacks were shown to have an earlier stage of renal cell carcinoma (RCC) at diagnosis compared to non-Hispanic Whites. It is less clear whether disparities in RCC staging occurs for other minority races/ethnicities. We aimed to assess the association between racial/ethnic minorities and stage at diagnosis of RCC, and test for potential effect modification by histological subtype. Read More

View Article and Full-Text PDF